NCT07094308

The LIFT-ECHO Last Mile Project

Not yet recruiting NA Last updated 12 March 2026

What this trial tests

NA trial testing Learn Intestinal Failure Tele-ECHO Program in Intestinal Failure in 150 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
30 June 2030

30 June 2030

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	health services research
Enrollment	150
Start date	1 July 2026
Primary completion	30 June 2030
Estimated completion	30 June 2030
Sites	5 locations across United Kingdom, United States

Drugs / interventions tested

• Learn Intestinal Failure Tele-ECHO Program
• Standard of Care

Conditions studied

• Intestinal Failure — all drugs for Intestinal Failure →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

5 and older, any sex, with Intestinal Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-site research study to evaluate the efficacy and effectiveness of the LIFT-ECHO program to improve clinical outcomes in patients and improve patient reported quality of life (PRQOL). LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a tele-health learning program whereby non-specialist clinicians meet with and learn from CIF specialist teams with the goal of improving the knowledge of CIF. LIFT-ECHO sessions consist of group discussion of anonymized real-world patient cases, followed by a didactic presentation from an expert in intestinal failure. Sessions are held twice a month and last 60-90 minutes. The study will proceed in three distinct phases, correlating with Project Aims. During phase 1 (Aim 1), an intestinal failure disease activity index (IF-DAI) will be developed as a measure of short- to medium-term clinical activity in CIF patients; this phase will be undertaken through Delphi Rounds. During Phase 2 (corresponding to project Aim 2), the researchers will evaluate the impact of physician participation in LIFT-ECHO on patients with CIF on PN. Lastly, Phase 3, corresponding to Aim 3 will be the dissemination of LIFT-ECHO nationally. For Phase 2, the researchers had originally proposed that patients and physicians will be recruited from the records of Optum Home Infusion services. Patient reported quality of life and clinical status will be assessed using surveys at baseline. Physicians will then be invited to participate in a module of LIFT-ECHO consisting of 8 one- hour-long sessions held over the course of 2-4 months. Patients will then be followed for 12 months to assess if physician participation in LIFT-ECHO improves patient reported quality of life and/or treatment efficacy and effectiveness. The main procedures for physician participants in the study include: completion of baseline and monthly surveys, possible participation in an appreciative inquiry workshop and possible participation in a focus group discussion, optional, but encouraged, participation in LIFT-ECHO. The main procedures for patient participants include: completion of surveys at baseline, participation in 12 monthly follow-up phone calls with a study team member. The proposed trial has a total length of 34 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.